| Company: Resverlogix Corp. Symbol: TSX: RVX Length: 00:20:29 |
Presenter: Donald J. McCaffrey, President and CEO Occasion: Richmond Club Lunch, Toronto |
Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials.
More About Resverlogix
New compounds arising from Resverlogix’s epigenetic drug development platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including neurodegenerative diseases and diabetes mellitus.
Our Business Model is to seek strategic opportunities through early alliance partnerships that are best suited to bring our technology platforms to successful commercialization. We are committed to good corporate governance and protection of shareholder value.
History
In 2000, Donald McCaffrey was President of BioFuture, a national conference that brought academia and industry together featuring prominent researchers from universities across North America and representatives from the biotechnology industry. Dr. Norman Wong, a clinician who had been researching atherosclerosis and ApoA-I, met Don while presenting at BioFuture 2000. During the conference they discussed the paradigm shift in the treatment of atherosclerosis from the reduction of LDL cholesterol to raising HDL cholesterol. With the common goal to develop better therapies for the treatment of cardiovascular diseases, Don and Norm founded Resverlogix. Their combined talent, along with the addition of instrumental new employees in science and business, formed the foundation that has made Resverlogix the success it is today.
Head Office:
Resverlogix Corp.
300, 4820 Richard Road SW
Calgary, AB, CANADA, T3E 6L1
Telephone: 1 631-756-9116
E: info@resverlogix.com
W: www.resverlogix.com
More About Resverlogix
New compounds arising from Resverlogix’s epigenetic drug development platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including neurodegenerative diseases and diabetes mellitus.
Our Business Model is to seek strategic opportunities through early alliance partnerships that are best suited to bring our technology platforms to successful commercialization. We are committed to good corporate governance and protection of shareholder value.
History
In 2000, Donald McCaffrey was President of BioFuture, a national conference that brought academia and industry together featuring prominent researchers from universities across North America and representatives from the biotechnology industry. Dr. Norman Wong, a clinician who had been researching atherosclerosis and ApoA-I, met Don while presenting at BioFuture 2000. During the conference they discussed the paradigm shift in the treatment of atherosclerosis from the reduction of LDL cholesterol to raising HDL cholesterol. With the common goal to develop better therapies for the treatment of cardiovascular diseases, Don and Norm founded Resverlogix. Their combined talent, along with the addition of instrumental new employees in science and business, formed the foundation that has made Resverlogix the success it is today.
Head Office:
Resverlogix Corp.
300, 4820 Richard Road SW
Calgary, AB, CANADA, T3E 6L1
Telephone: 1 631-756-9116
E: info@resverlogix.com
W: www.resverlogix.com
